Form 4: Ocular Therapeutix Director Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Seung Suh Hong was granted 14,000 restricted stock units and 44,000 stock options by Ocular Therapeutix, Inc.
Summary
- Director Seung Suh Hong received a grant of 14,000 restricted stock units (RSUs) on June 10, 2026.
- The director was also granted 44,000 stock options with an exercise price of $8.74 per share.
- Both the RSUs and stock options are subject to a one-year vesting schedule, contingent upon continued service on the board of directors.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Equity-based compensation aligns the interests of the director with those of the shareholders.
- The grant structure encourages long-term retention of board members.
Negatives
- The issuance of new equity results in minor dilution for existing shareholders.
Risks
- Vesting is contingent upon continued service, which could be impacted by unforeseen changes in board composition.
Future Outlook
The equity grants are subject to a one-year vesting period, aligning the director's incentives with the company's performance through at least June 2027.
Management Comments
- The grants were issued under the 2021 Stock Incentive Plan, as amended.
Industry Context
StockSavvy.ai notes that standard equity compensation for board members is a common practice in the biotechnology sector to ensure leadership stability and alignment with long-term corporate milestones.
Comparison to Industry Standards
- The use of a one-year vesting cliff for director equity is consistent with standard corporate governance practices for mid-cap biotech firms.
- The grant size is typical for non-executive director compensation packages in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of RSUs and stock options to a director. | 06/10/2026 | Standard alignment of director incentives with shareholder interests. |
Stakeholder Impact
- Shareholders experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of the RSUs and stock options on the first anniversary of the grant date or the next annual meeting of stockholders.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of the equity grant transaction. |
| 06/12/2026 | Date the Form 4 was filed with the SEC. |
| 06/09/2036 | Expiration date for the granted stock options. |
Keywords
Ocular Therapeutix, OCUL, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.